Basic Information
DATSCAN SOLUTION FOR INJECTION 74 MBQ/ML
INJECTION, SOLUTION
Regulatory Information
SIN15325P
September 4, 2017
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
May 30, 2025
XV09AB03
Company Information
Active Ingredients
Strength: 74 MBq/mL at reference time
Detailed Information
Contraindications
**4.3 Contraindications** - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. - Pregnancy (see section 4.6 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**4.1 Therapeutic indications** DaTSCAN is a radiopharmaceutical indicated for striatal dopamine transporter visualisation using single photon emission computed tomography (SPECT) brain imaging to assist evaluation: - In adult patients with clinically uncertain Parkinsonian Syndromes, for example those with early symptoms, in order to help differentiate Essential Tremor from tremor due to Parkinsonian Syndromes related to idiopathic Parkinson's Disease, Multiple System Atrophy and Progressive Supranuclear Palsy. DaTSCAN is unable to discriminate between Parkinson's Disease, Multiple System Atrophy and Progressive Supranuclear Palsy. - In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer's disease. DaTSCAN is unable to discriminate between dementia with Lewy bodies and Parkinson's disease dementia. DaTSCAN is an adjunct to other diagnostic evaluations.